TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23652031
Drug: Progesterone gel
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone gel (80 mg applied daily for 14 days)
Study: 23652031
Drug: Progesterone cream
Normalized name: NATURAL PROGESTERONE CREAM,TOP
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone cream
Study: 2345268
Drug: Progesterone gel
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone gel
Study: 17094038
Drug: Antenatal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal treatment with intravenous gammaglobulin (IVIG) and/or corticosteroids
Study: 19737980
Drug: Liraglutide 0.6
Normalized name: liraglutide 0.6 mg/0.1 mL (18 mg/3 mL) SUBCUT PEN INJECTOR (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 0.6 mg
Study: 11298254
Drug: Medication information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication information leaflets in addition to verbal information
Study: 11298254
Drug: Verbal medication
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verbal medication information by nurse or psychiatrist (Control)
Study: 7937786
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of the advanced glycation inhibitor aminoguanidine to diabetic patients
Study: 2908716
Drug: Trimazosin 50
Normalized name: trimazosin
DrugBank: Trimazosin (DB09206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimazosin 50 mg twice daily
Study: 2908716
Drug: Trimazosin 100
Normalized name: trimazosin
DrugBank: Trimazosin (DB09206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimazosin 100 mg twice daily
Study: 2908716
Drug: Trimazosin 200
Normalized name: trimazosin
DrugBank: Trimazosin (DB09206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimazosin 200 mg twice daily
Study: 23639861
Drug: Bowman Birk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowman Birk Inhibitor (BBI) complex
Study: 21624036
Drug: Propylthiouracil (PTU)
Normalized name: Propylthiouracil
DrugBank: Propylthiouracil (DB00550)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propylthiouracil (PTU) treatment during pregnancy
Study: 21624036
Drug: Methimazole/carbimazole (MMI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole/carbimazole (MMI) treatment during pregnancy
Study: 18400462
Drug: Conventional care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional care (CC)
Study: 1402218
Drug: labetalol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: labetalol (200 mg t.t.d.)
Study: 1402218
Drug: acebutolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: acebutolol (200 mg t.t.d.)
Study: 1402218
Drug: metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol (100 mg t.t.d.)
Study: 31234665
Drug: Abbreviated schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abbreviated schedule with three injections at weekly intervals
Study: 16390397
Drug: Isoniazid (INH)
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid (INH) chemoprophylaxis, daily for 1 year
Study: 7805428
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg ciprofloxacin twice daily for 9 days
Study: 7805428
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg ciprofloxacin twice daily for 9 days
Study: 3383985
Drug: Magnesium pyridoxal
Normalized name: magnesium pyridoxal 5-phosphate glutamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium pyridoxal 5‐phosphate glutamate (MPPG) 3 x 50 mg for 12 weeks
Study: 25099545
Drug: Intraduodenal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal protein infusion (hydrolyzed whey) 180 kcal
Study: 25099545
Drug: Control (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (saline infusion, 0 kcal)
Study: 22267334
Drug: Conventional immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional immunosuppressive (IS) treatment
Study: 18520801
Drug: Cisplatin (CDDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CDDP) 80 mg/m on day 1 and Vinorelbine (VNR) 20 mg/m on days 1 and 8 every 4 weeks with concurrent thoracic radiotherapy (TRT) of 60 Gy in 30 fractions.
Study: 12028321
Drug: Frovatriptan (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frovatriptan (oral administration)
Study: 10496576
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen treatment (100% oxygen for 1 hour per day at 2.0 atm)
Study: 10496576
Drug: 5-day hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day hyperbaric oxygen treatment (100% oxygen for 1 hour per day at 2.0 atm)
Study: 10496576
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (21% oxygen for 1 hour per day at 1.2 atm)
Study: 2453895
Drug: Buprenorphine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (0.3 mg)
Study: 31985248
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and commitment therapy (manualized intervention)
Study: 19398279
Drug: Preparing for
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparing for the Drug Free Years (PDFY)
Study: 16317266
Drug: Erlotinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (50 mg/d) with chemoradiation.
Study: 2702966
Drug: Adenosine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (maximum tolerated dose: 10.3 +/- 2.3 mg)
Study: 31289092
Drug: 4 L split‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 L split‐dose polyethylene glycol electrolyte solution (PEG‐ELS) preceded by 15 mg of bisacodyl and a low-fibre diet
Study: 31289092
Drug: 6 L split‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 L split‐dose polyethylene glycol electrolyte solution (PEG‐ELS) preceded by 15 mg of bisacodyl and a low-fibre diet
Study: 31289092
Drug: 6 L split‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 L split‐dose PEG‐ELS
Study: 31289092
Drug: 4 L split‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 L split‐dose PEG‐ELS
Study: 12946073
Drug: Control side
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control side (no AMSA injection)
Study: 3027604
Drug: Yohimbine (effective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (effective dose)
Study: 28028194
Drug: Allopurinol (300-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (300-600 mg/d)
Study: 27909139
Drug: SBI-087 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBI-087 (200 mg)
Study: 24828019
Drug: Folate-5: 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folate-5: 5 mg/day folate supplements
Study: 24828019
Drug: Folate-1: 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folate-1: 1 mg/day folate supplements
Study: 21751197
Drug: 15 mg/m²
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/m² clofarabine daily × 5 days
Study: 8881132
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose of nadroparin calcium (7500 anti-Xa IC units)
Study: 21890277
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized progesterone (300 mg)
Study: 1576050
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized progesterone (600 mg)
Study: 1576050
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized progesterone (1200 mg)
Study: 28127561
Drug: Traditional immunosuppressants
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional immunosuppressants
Study: 23023231
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose plain radiography
Study: 18312042
Drug: OROS methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS methylphenidate (18 mg to 54 mg)
Study: 12421104
Drug: Bicalutamide 150
Normalized name: bicalutamide 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide 150 mg/day
Study: 9333057
Drug: Oral levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral levofloxacin 500 mg
Study: 8471403
Drug: Fengabine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fengabine 400 mg
Study: 3836854
Drug: 40 749
Normalized name: petrolatum 0.749 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 749 RP (2 mg/kg)
Study: 29220295
Drug: Cisplatin 30
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 30 mg/m2 given once a week
Study: 29220295
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2 given once every 3 weeks
Study: 19477881
Drug: Nicotine (Nicorette
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (Nicorette 2 mg)
Study: 18705297
Drug: Mesalazine 800mg/daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine 800mg/daily (group M1)
Study: 11151579
Drug: 2‐stage endosseous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2‐stage endosseous root‐form implants (3 different implant systems)
Study: 6363395
Drug: Rapid intramuscular
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid intramuscular neuroleptization at 2 mg per dose
Study: 29898587
Drug: BoNT‐A monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT‐A monotherapy (N=18)
Study: 15246905
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral nitrates
Study: 15246905
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily oral nitrates
Study: 24602137
Drug: HM30181 (15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM30181 (15, 60, or 180 mg)
Study: 9197805
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for STD (Comparison Group)
Study: 31686094
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (LipiDiDiet product)
Study: 25951165
Drug: L-carnitine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (2 g in 1000 mL of 0.9% saline solution infused over 24 hours for each of the 3 preoperative days)
Study: 25951165
Drug: Placebo (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1000 mL of 0.9% saline solution for the same time period)
Study: 22770431
Drug: Conventional bleaching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional bleaching technique with 38% hydrogen peroxide gel for one hour
Study: 22770431
Drug: Sealed bleaching
Normalized name: GOLDEN SEAL
DrugBank: Goldenseal (DB16594)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sealed bleaching technique with 38% hydrogen peroxide gel for one hour
Study: 16820257
Drug: Reboxetine 4
Normalized name: reboxetine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine 4 mg/day bid + Sertraline 50 mg/day od
Study: 10678926
Drug: Lower-dose vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose vaccine (5 x 10(7) CFU)
Study: 10678926
Drug: Both high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both high-dose and lower-dose vaccines
Study: 8290185
Drug: 30-minute incremental
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-minute incremental oxytocin infusion regimen
Study: 8290185
Drug: 15-minute incremental
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-minute incremental oxytocin infusion regimen
Study: 2566779
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment for 4 months
Study: 27677865
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of prednisone
Study: 1097222
Drug: Maintenance administration
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance administration of prednisone
Study: 1097222
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of prednisone when headaches began
Study: 17876505
Drug: Methylphenidate combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate combined with multimodal behavior therapy
Study: 16426470
Drug: Meperidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 0.5 mg kg(‐1)
Study: 14557583
Drug: L-DOPA (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-DOPA (400 mg/day)
Study: 10848743
Drug: Amorolfine 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amorolfine 5% solution nail lacquer + oral terbinafine for 6 weeks (AT6 group)
Study: 10848743
Drug: Amorolfine 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amorolfine 5% solution nail lacquer + oral terbinafine for 12 weeks (AT12 group)
Study: 7907662
Drug: Intravenous L-2-oxothiazolidine-4-carboxylic
Normalized name: L-2-oxothiazolidine-4-carboxylic acid
DrugBank: Oxothiazolidinecarboxylic acid (DB12224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous L-2-oxothiazolidine-4-carboxylic acid (Procysteine) at 3, 10, or 30 mg/kg
Study: 7907662
Drug: Intravenous L-2-oxothiazolidine-4-carboxylic
Normalized name: L-2-oxothiazolidine-4-carboxylic acid
DrugBank: Oxothiazolidinecarboxylic acid (DB12224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous L-2-oxothiazolidine-4-carboxylic acid (Procysteine) at 100 mg/kg
Study: 7907662
Drug: Intravenous L-2-oxothiazolidine-4-carboxylic
Normalized name: L-2-oxothiazolidine-4-carboxylic acid
DrugBank: Oxothiazolidinecarboxylic acid (DB12224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous L-2-oxothiazolidine-4-carboxylic acid (Procysteine)
Study: 2640452
Drug: Furosemide (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (0.5 mg/kg body weight)
Study: 18155050
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine 5 mg per mL
Study: 18155050
Drug: Intrathecal ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal ropivacaine 10 mg per mL
Study: 17184102
Drug: Esterified conjugated
Normalized name: estrogens, conjugated (USP) / estrogens, esterified (USP) / medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esterified conjugated estrogens (ECE) 0.312 mg/day (low‐dose) (n = 17)
Study: 9093637
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg DEC
Study: 9093637
Drug: DEC (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEC (various doses)
Study: 2866071
Drug: Rectal biopsies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal biopsies
Study: 27321474
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral progesterone daily
Study: 12014812
Drug: Therapeutic community
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic community (TC) treatment
Study: 7092633
Drug: Topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical timolol maleate 0.5%, one drop every 12 hours
Study: 31646623
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no nicotine patches)
Study: 14973800
Drug: Intravenous quinaprilat
Normalized name: quinaprilat
DrugBank: Quinaprilat (DB14217)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous quinaprilat (0.08 mg/kg)
Study: 14973800
Drug: Intravenous isotonic
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous isotonic saline solution
Study: 9042869
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition enriched with omega-3 fatty acids
Study: 8037492
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of chemotherapy with G‐CSF or bone marrow transplantation
Study: 8037492
Drug: New promising
Approvals — FDA: no, EMA: no, PMDA: no
Description: New promising drugs for chemotherapy such as taxanes
Study: 17146380
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg amitriptyline at bedtime
Study: 29668720
Drug: Mechanical periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical periodontal therapy plus adjunctive antibiotics (amoxicillin 500 mg and metronidazole 400 mg, 3x/day for 7 days)
Study: 26234336
Drug: Memantine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (20 mg)
Study: 12644421
Drug: Onset of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onset of neuromuscular block after vecuronium (0.1 mg kg(‐1)) in diabetic patients
Study: 8436148
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg/d (increased to 40 mg/d if necessary)
Study: 31916979
Drug: Standard six
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard six cycle IV carboplatin‐paclitaxel chemotherapy (CP)
Study: 29575254
Drug: Paclitaxel (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (175 mg/m2) and nedaplatin (80 mg/m2) administered every 28 days for 5 cycles after radical hysterectomy
Study: 27404673
Drug: tolvaptan treatment
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: tolvaptan treatment for 2 days
Study: 20015605
Drug: Gender-responsive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gender-responsive treatment (GRT) program using manualized curricula (Helping Women Recover and Beyond Trauma)
Study: 20015605
Drug: Gender-responsive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gender-responsive treatment (GRT) program
Study: 11428976
Drug: Acyclovir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (800 mg qid for 12 weeks)
Study: 1837113
Drug: CB006 (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: CB006 (0.4 mg/kg)
Study: 1837113
Drug: CB006 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CB006 (2 mg/kg)
Study: 6228938
Drug: Dihydroergotoxine mesylate
Normalized name: Dihydroergotoxine mesylate
DrugBank: Dihydroergotoxine (DB16602)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotoxine mesylate (DHT) 1.5 mg t.i.d.
Study: 29762690
Drug: Early antiretroviral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early antiretroviral treatment in HIV‐1‐positive infants
Study: 22209388
Drug: MRC-only (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRC-only (8 individual motivational enhancement sessions and 16 treatment readiness group sessions)
Study: 7698680
Drug: GnRH analog
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH analog (10 micrograms, 2 intravenous pulses)
Study: 7698680
Drug: GnRH injection
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH injection
Study: 338136
Drug: MAC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAC therapy (Adriamycin + Melphalan + Cyclophosphamide)
Study: 338136
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy (Cyclophosphamide + Methotrexate + 5-Fluorouracil) after induction therapy
Study: 27771973
Drug: Amisulpride (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (50 mg)
Study: 21126861
Drug: Clear carbohydrate
Normalized name: Ensure Pre-Surgery Clear Carbohydrate Drink (Strawberry)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear carbohydrate drink (CCD) containing 50 g of carbohydrate
Study: 21126861
Drug: Drink containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drink containing 50 g of carbohydrate, 15 g of glutamine, and antioxidants (ONS)
Study: 15955273
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous immunoglobulins (IVIg)
Study: 10569649
Drug: TNK-tPA 30
Normalized name: TNK-tPA
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TNK-tPA 30 mg
Study: 10569649
Drug: TNK-tPA 50
Normalized name: TNK-tPA
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TNK-tPA 50 mg
Study: 2520619
Drug: ORS with
Normalized name: SODIUM FLUORIDE 2.43 mg in 1 g ORAL PASTE, DENTIFRICE [Dr Tichenors With Extra Whitening and Tartar Control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORS with high sodium but low glucose concentration (Na+ 60, glucose 111 mmol/L)
Study: 2520619
Drug: ORS containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORS containing glycine and a glucose polymer (Na+ 50, glucose 50, glycine 50 mmol/L)
Study: 5572682
Drug: Condensed polyphenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Condensed polyphenol inhalation by byssinotic cardroom workers
Study: 5572682
Drug: Condensed polyphenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Condensed polyphenol inhalation by normal control subjects and non-byssinotic cardroom workers
Study: 23817340
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose (20 mg/kg)
Study: 23817340
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose (30 mg/kg)
Study: 21933752
Drug: Raltegravir once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir once daily (two 400 mg tablets taken together every 24 h)
Study: 21933752
Drug: Raltegravir twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir twice daily (one 400 mg tablet every 12 h)
Study: 23807156
Drug: Raltegravir twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir twice daily
Study: 31926000
Drug: ASP8062 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP8062 (single ascending doses)
Study: 23832433
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of curcumin and fluoxetine